feedback

Course Directors

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP

Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Robert Z. Orlowski, MD, PhD
Robert Z. Orlowski, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

In this PeerView “How I Think, How I Treat” CME video activity, multiple myeloma (MM) experts explore the era of antibody-based therapy and the implications of new science for treatment decisions from early disease settings through the management of relapsed/refractory MM. By sharing their personal insights and intra-institutional experiences, and combining these reflections with in-depth analysis of recent evidence on anti-CD38, SLAMF7, and BCMA-targeting antibodies, Drs. Sagar Lonial and Robert Z. Orlowski recommend ways to improve clinical outcomes related to the integration of antibody therapy into modern MM management. Don’t miss this opportunity to get informed on the unique anticancer mechanisms of antibody-based therapy, as well as the safety and efficacy evidence supporting its use across the wide spectrum of MM presentations.

Upon completion of this activity, participants should be better able to:
  • Summarize the therapeutic targets and mechanisms associated with novel antibodies in multiple myeloma, including CD38, SLAMF7, and BCMA, among others
  • Discuss current efficacy and safety evidence surrounding the use of novel and next-generation antibodies in patients with newly diagnosed or relapsed/refractory multiple myeloma
  • Develop personalized treatment regimens with novel antibody components for patients with newly diagnosed or relapsed/refractory multiple myeloma
  • Manage practical considerations related to the use of antibody-based regimens in multiple myeloma, including unique adverse events, dosing considerations, and interference with blood compatibility testing, among others

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, and clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: September 30, 2020 - September 29, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support Board of Directors for TG Therapeutics, Inc.

Co-Chair
Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Director, Myeloma Section, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; Celgene Corporation; EcoR1 Capital LLC; Forma Therapeutics; Genzyme; GlaxoSmithKline Biologicals; Ionis Pharmaceuticals, Inc.; Janssen Biotech, Inc.; Juno Therapeutics, Inc.; Kite Pharma; Legend Biotech; Molecular Partners; Regeneron Pharmaceuticals, Inc.; Sanofi; Servier Laboratories; STATinMED, Research; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from BioTheryX, Inc.; CARsgen Therapeutics; Celgene Corporation; Exelixis, Inc.; Janssen Biotech, Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not directly bear on the current activity.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6668-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.